PRISM (Proteomics, Inflammatory Response & Mass Spectrometry) Laboratory is one of the laboratories of the Biology Department of Faculty of Sciences and Technologies at University of Lille (ULille). PRISM has been created as U1192 Inserm Unit the 01/01/2015. PRISM is historically located on the 1st floor of the SN3 building at the campus Cité Scientifique of the University of Lille (former University Lille 1 Science & Technology). PRISM covers 800m2 on the first floor of the building plus 100m2 shared with Inserm U1003 on the second floor. Since 2013, PRISM is also partially located at the Faculty of Medicine of University of Lille at the hospital campus at the the Regional Cancer Comprehensive Center of Lille, Centre Oscar Lambret (COL) and recently at the Institute of Cancer Research of Lille (2023) for translational researches. Indeed, since 2005, tight collaborations in the field of oncology were established between the laboratory and clinicians from the team of Prof. D. Vinatier at the Department of Gynecology of Lille University Hospital (CHRU Lille). This collaboration was consolidated by the integration of the team of Prof. E. Leblanc since 2013 then pathologist team led By Yves-Marie Robin in 2014 then the senologist N. Hajjjaji (2018) and the neuroendocrinologist Dr. Sandra Raimbault more recently (2022) of COL. Finally, neurooncologists from the Neurosurgery Department of Lille Hospital have also been integrated. Agreements have been signed with COL at the end of 2012 and later in 2013 with the CHRU Lille for the integration of clinicians into the lab. Lille hospital is, since 2015, with Inserm and University of Lille, the administrative supervision of PRISM and COL since 2020 the secondary administrative supervision. Ten clinicians have joined PRISM including surgeons, pathologists and oncologists since 2013.
The laboratory is organized as a single-team unit around two main axes, the first one being devoted to Technological Innovations and the second to Therapeutic Innovations. PRISM is co-directed by Pr. M. Salzet and Pr. I. Fournier.
The Technological Innovation pillar is supervised by Prof. I Fournier and has emerged in 2004 as the MALDI Imaging Team (MIT). Since 2004, MIT research were focused on i) technological developments and ii) clinical applications transversally to the second axis of theunit. MIT targets since its beginnings on the development of MALDI MSI first with improvements in i) tissue preparation for both Fresh frozen and Formalin–Fixed Paraffin-Embedded (FFPE) samples and ii) biomolecules identification with preserved spatial localization. This was pursed through the development of novel MALDI matrices (ionic matrices), of matrix deposition methods (spraying devices, automatic spotting with piezoelectric head), on-tissue micro-digestion and on-tissue tryptic peptide derivatization, unlocking FFPE tissue, bioinformatics (novel imaging software, MITICS, Principal-Component Analysis-Symbolic Discriminant Analysis method (PCA-SDA) and now deep-learning), novel pre-spotted MALDI plates with ionic matrices, as well as targeted MALDI-MSI based on Tag-Mass, so called MALDI IHC multiplex. More recently MIT has developed a new technology for real-time mass spectrometry analyses, the SpiderMass technology based on WALDI-MS. SpiderMass is devoted to help surgeon for decision making based on real-time molecular profile analysis.
The Therapeutic Innovation pillar is directed by Prof. M. Salzet and is issued from the UMR CNRS 8017 in 2000 on Leech and mammals neuroimmunology. In 2002, the unit demonstrated the expression of neuroendocrine factors in macrophages and their role in the immune response and dissect their involvement in immune response modulation. This conducts to get the ability to reprogram macrophages based on the inactivation of one key enzyme involve in neuropeptide precursors, the proprotein convertase PC1/3. This strategy was developed for anti-tumoral therapy. In a mirror aspect, we investigated the presence and the role of immune factors in nervous system. Most of these factors are involved in neurogenesis and neurites outgrowth control especially in microglia cells and in astrocytes. We recently demonstrated expression of neural immunoglobulins involved as gatekeepers of astrocytes fate. At a larger extend we now investigate these neural Ig in glioblastoma. Thus, crosstalk investigation between both neuroendocrine (normal or cancer) and immune cells will be one of the objective of this pillar.
